ACADIA Pharmaceuticals Q2 2024 GAAP EPS $0.20 Beats $0.18 Estimate, Sales $241.963M Beat $235.418M Estimate
Portfolio Pulse from Benzinga Newsdesk
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported Q2 2024 earnings per share (EPS) of $0.20, surpassing the analyst estimate of $0.18. The company also reported sales of $241.963 million, exceeding the estimate of $235.418 million. This represents a significant year-over-year increase in both EPS and sales.
August 06, 2024 | 8:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ACADIA Pharmaceuticals reported Q2 2024 EPS of $0.20, beating the estimate of $0.18, and sales of $241.963 million, surpassing the estimate of $235.418 million. This indicates strong financial performance and significant year-over-year growth.
The company's EPS and sales both exceeded analyst estimates, indicating strong financial performance. The significant year-over-year growth in both metrics is likely to positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100